Danish company puts its heart into innovation  

Innovision has just launched a groundbreaking product for monitoring cardiac efficiency

Funen based company Innovision has completed the development of a new groundbreaking cardiac monitoring instrument, Innocor, which according to a report in financial newspaper Børsen has the potential to become a major success on the world market. By measuring the patient's expired breath, Innocor can register how efficiently the heart is pumping blood. Until now, this knowledge has otherwise only been achievable invasively by inserting a catheter into the veins of the heart.


Innocor will initially be marketed to the world's leading cardiologists and later to the entire hospital sector at a price per instrument in the approximate region of DKK 175,000 (approx. USD 23,000). A US company competing in the same product area assesses the world market to be worth about DKK 10 billion (USD 1.3 billion) a year. Innovision is owned by Lønmodtagernes Dyrtidsfond and Dansk Kapitalanlæg, among others.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×